Fundz

Verdiva Bio Limited raised $411M in a Series A funding led by Forbion and General Atlantic to develop innovative therapies for obesity and cardiometabolic disorders.

PRIVATEJan 09, 2025

Amount Raised

$411 Million

Round Type

Series A

LondonBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Investors

OrbimedGeneral AtlanticForbionRA Capital ManagementLYFE CapitalLilly Asia VenturesLogos Capital

Description

Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company with an oversubscribed Series A financing of $411M. The funding will be used to advance a portfolio of next-generation oral and injectable treatments aimed at addressing obesity and related disorders.

Who to call at Verdiva Bio, and when

A new round usually means Verdiva Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Verdiva Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Verdiva Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Verdiva Bio. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Verdiva Bio

Location

London, England, United Kingdom

About

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Verdiva Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Verdiva Bio's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Verdiva Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.